Zhejiang Jingxin Pharmaceutical Co Ltd (002020) — Cash Flow Reinvestment Rate
Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has a Cash Flow Reinvestment Rate of 0.16x as of September 2025, reinvesting CN¥35.55 Million (capex CN¥35.55 Million ) from operating cash flow of CN¥227.64 Million. Explore Zhejiang Jingxin Pharmaceutical Co Ltd capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Zhejiang Jingxin Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2002–2025)
Historical reinvestment intensity for Zhejiang Jingxin Pharmaceutical Co Ltd across 22 annual periods. Also explore how large is Zhejiang Jingxin Pharmaceutical Co Ltd's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Zhejiang Jingxin Pharmaceutical Co Ltd (2002–2025)
Year-by-year capital reinvestment analysis for Zhejiang Jingxin Pharmaceutical Co Ltd. For live market cap and broader valuation context, see 002020 company net worth.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.98x | CN¥768.92 Million | CN¥781.35 Million | CN¥202.85 Million | ▼ -50.0% |
| 2024 | 1.97x | CN¥1.43 Billion | CN¥726.16 Million | CN¥250.65 Million | ▲ +29.1% |
| 2023 | 1.52x | CN¥1.26 Billion | CN¥824.69 Million | CN¥519.51 Million | ▲ +52.0% |
| 2022 | 1.00x | CN¥857.97 Million | CN¥855.78 Million | CN¥515.57 Million | ▼ -59.9% |
| 2021 | 2.50x | CN¥912.77 Million | CN¥365.02 Million | CN¥404.43 Million | ▲ +23.2% |
| 2020 | 2.03x | CN¥1.04 Billion | CN¥513.21 Million | CN¥334.00 Million | ▲ +196.3% |
| 2019 | 0.68x | CN¥366.65 Million | CN¥535.30 Million | CN¥337.33 Million | ▲ +45.5% |
| 2018 | 0.47x | CN¥246.39 Million | CN¥523.40 Million | CN¥242.19 Million | ▼ -86.4% |
| 2017 | 3.45x | CN¥1.33 Billion | CN¥385.01 Million | CN¥112.19 Million | ▲ +68.1% |
| 2016 | 2.05x | CN¥519.01 Million | CN¥252.69 Million | CN¥95.26 Million | ▲ +96.8% |
| 2015 | 1.04x | CN¥151.04 Million | CN¥144.69 Million | CN¥114.31 Million | ▲ +131.9% |
| 2014 | 0.45x | CN¥94.75 Million | CN¥210.49 Million | CN¥94.75 Million | ▼ -53.8% |
| 2013 | 0.98x | CN¥108.28 Million | CN¥111.03 Million | CN¥108.28 Million | ▼ -29.6% |
| 2012 | 1.39x | CN¥83.51 Million | CN¥60.28 Million | CN¥83.51 Million | ▲ +33.8% |
| 2011 | 1.04x | CN¥71.86 Million | CN¥69.41 Million | CN¥71.86 Million | ▼ -60.4% |
| 2010 | 2.62x | CN¥155.87 Million | CN¥59.55 Million | CN¥155.87 Million | ▲ +1655.7% |
| 2009 | 0.15x | CN¥20.18 Million | CN¥135.38 Million | CN¥20.18 Million | ▼ -89.8% |
| 2008 | 1.46x | CN¥43.81 Million | CN¥29.98 Million | CN¥43.81 Million | ▼ -32.9% |
| 2005 | 2.18x | CN¥134.67 Million | CN¥61.82 Million | CN¥134.67 Million | ▼ -85.7% |
| 2004 | 15.26x | CN¥98.11 Million | CN¥6.43 Million | CN¥98.11 Million | ▲ +889.6% |
| 2003 | 1.54x | CN¥71.19 Million | CN¥46.18 Million | CN¥71.19 Million | ▲ +46.8% |
| 2002 | 1.05x | CN¥47.79 Million | CN¥45.50 Million | CN¥47.79 Million | — |